Abstract: Objective: To discuss whether neoadjuvant chemotherapy could increase the survival rate of patients with advanced-stage breast carcinoma Methods: Clinic data of 142 patients with advanced breast carcinoma was summarized, and all patients were followed up. Results: Of the 75 patients who had received preoperative chemotherapy, there was complete response (CR) patients 13 (17.3%), including 5 (6.7%) patients with pathological complete response (pCR), 44 (58.7%) with partial response (PR), 12(16.0%) with stable disease (SD), and 52 patients were treated with radical surgery, including 16 with stage-Ⅳ breast cancer. The two-year overall survival (OS) was 76.0% (57/75) and relapse-free survival (RFS) was 48.0% (36/75). On the other hand, of the other patients who had not received preoperative chemotherapy, 35 (52.2%) of them were treated with radical surgery. The two-year OS was 56.7% (38/67) (χ²=5.9, P<0.05) and RFS was 29.9% (20/67) (χ²=4.9, P<0.05). Conclusion: Preoperative chemotherapy could decrease the TNM stage and part of the stage-Ⅳ patients can be treated by radical surgery. It will benefit the survival of patients with advanced breast cancer.